Related Experiment Videos
5 alpha-reductase inhibitors: what's new?
Charlotte L Foley1, Roger S Kirby
1Prostate Cancer Research Unit, Institute of Urology and Nephrology, University College London, 67 Riding House Street, London W1W 7EY, UK. charlotte.foley@ucl.ac.uk
Current Opinion in Urology
|December 20, 2002
Summary
5 alpha-reductase inhibitors are key for benign prostatic hyperplasia (BPH) treatment. New dual-isoenzyme inhibitors offer enhanced DHT suppression, potentially improving BPH outcomes and exploring roles in prostate cancer prevention.
Area of Science:
- Urology
- Pharmacology
- Oncology
Background:
- Benign prostatic hyperplasia (BPH) is commonly treated with medical therapy.
- 5 alpha-reductase inhibitors are a cornerstone of BPH management.
- Understanding their evolving roles is crucial for patient care.
Purpose of the Study:
- To review recent advancements in 5 alpha-reductase inhibitor usage for BPH.
- To highlight the introduction of dual isoenzyme inhibitors.
- To explore emerging applications of these drugs.
Main Methods:
- Review of recent clinical trials and pharmacological studies.
- Analysis of data on finasteride and the novel dutasteride.
- Evaluation of combination therapy versus monotherapy outcomes.
Main Results:
- Dutasteride inhibits both type 1 and type 2 5-alpha reductase isoenzymes, achieving greater DHT suppression than finasteride.
- Clinical trials suggest dutasteride is comparable to finasteride in improving BPH symptoms and reducing adverse events.
- Combination therapy demonstrated superior outcomes in a recent large trial.
- 5 alpha-reductase inhibitors show potential in managing BPH-related hematuria and chemoprevention of prostate cancer.
Conclusions:
- 5 alpha-reductase inhibitors play a clarified and expanding role in BPH management.
- Dual isoenzyme inhibition with dutasteride offers a new therapeutic option.
- Further research is needed to confirm chemopreventive benefits for prostate cancer.